Literature DB >> 27883295

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Tristan M Sissung1, John Deeken2, Crystal R Leibrand1, Douglas K Price3, Sheryl Ehrlich3, Seth M Steinberg4, David J Liewehr4, William Dahut5, William D Figg1,3.   

Abstract

AIM: Metabolism and transport play major roles in life-long exposure to endogenous and exogenous carcinogens. We therefore explored associations between polymorphisms in absorption, distribution, metabolism and elimination genes and the risk and prognosis of castration-resistant prostate cancer (CRPC). MATERIALS &
METHODS: A total of 634 genotypes were tested in 74 patients using the Affymetrix DMETv1.0 platform.
RESULTS: No relation to risk was found. Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15). Two other polymorphisms among Caucasians were associated with interesting trends: ABCB4 rs2302387C>T (p = 0.039) and ABCC5 rs939339A>G (p = 0.018).
CONCLUSION: This exploratory study is the first to show that polymorphisms in several absorption, distribution, metabolism and elimination genes may be associated with CRPC prognosis.

Entities:  

Keywords:  castration-resistant prostate cancer; genotype; metabolism; outcome; survival; transport

Mesh:

Substances:

Year:  2016        PMID: 27883295      PMCID: PMC5558514          DOI: 10.2217/pgs-2016-0134

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  32 in total

1.  Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population.

Authors:  M Murata; M Watanabe; M Yamanaka; Y Kubota; H Ito; M Nagao; T Katoh; T Kamataki; J Kawamura; R Yatani; T Shiraishi
Journal:  Cancer Lett       Date:  2001-04-26       Impact factor: 8.679

2.  Variant in sex hormone-binding globulin gene and the risk of prostate cancer.

Authors:  Sonja I Berndt; Nilanjan Chatterjee; Wen-Yi Huang; Stephen J Chanock; Robert Welch; E David Crawford; Richard B Hayes
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-01       Impact factor: 4.254

3.  Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.

Authors:  Akinobu Hamada; Romano Danesi; Douglas K Price; Tristan Sissung; Cindy Chau; David Venzon; Alex Sparreboom; William L Dahut; William D Figg
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

4.  A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.

Authors:  J F Deeken; T Cormier; D K Price; T M Sissung; S M Steinberg; K Tran; D J Liewehr; W L Dahut; X Miao; W D Figg
Journal:  Pharmacogenomics J       Date:  2009-12-29       Impact factor: 3.550

5.  Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan.

Authors:  M Murata; T Shiraishi; K Fukutome; M Watanabe; M Nagao; Y Kubota; H Ito; J Kawamura; R Yatani
Journal:  Jpn J Clin Oncol       Date:  1998-11       Impact factor: 3.019

6.  A polymorphism in the CYP17 gene is associated with prostate cancer risk.

Authors:  A Gsur; G Bernhofer; S Hinteregger; G Haidinger; G Schatzl; S Madersbacher; M Marberger; C Vutuc; M Micksche
Journal:  Int J Cancer       Date:  2000-08-01       Impact factor: 7.396

7.  Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.

Authors:  Cinzia Antognelli; Luigi Mearini; Vincenzo Nicola Talesa; Antonella Giannantoni; Ettore Mearini
Journal:  Prostate       Date:  2005-05-15       Impact factor: 4.104

8.  Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.

Authors:  Y Yamada; M Watanabe; M Murata; M Yamanaka; Y Kubota; H Ito; T Katoh; J Kawamura; R Yatani; T Shiraishi
Journal:  Int J Cancer       Date:  2001-06-01       Impact factor: 7.396

9.  A polymorphism in the CYP17 gene and risk of prostate cancer.

Authors:  Janet L Stanford; Elizabeth A Noonan; Lori Iwasaki; Suzanne Kolb; Robert B Chadwick; Ziding Feng; Elaine A Ostrander
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-03       Impact factor: 4.254

10.  Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk.

Authors:  Bao-li Chang; Siqun L Zheng; Sarah D Isaacs; Aubrey Turner; Gregory A Hawkins; Kathy E Wiley; Eugene R Bleecker; Patrick C Walsh; Deborah A Meyers; William B Isaacs; Jianfeng Xu
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

View more
  1 in total

Review 1.  Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.

Authors:  Reka Varnai; Leena M Koskinen; Laura E Mäntylä; Istvan Szabo; Liesel M FitzGerald; Csilla Sipeky
Journal:  Genes (Basel)       Date:  2019-08-08       Impact factor: 4.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.